Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys CYTK Stock
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Ray Cisneros Jr. (D)
- Status:
- Member — House
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jul 2, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Cytokinetics, Incorporated ($CYTK) | Buy | Jun 30, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document.
Key Points
- Representative Gilbert Ray Cisneros Jr. bought shares of Cytokinetics, Incorporated in a transaction valued between $1,001 and $15,000 on June 30, 2026.
- Cytokinetics trades with a market capitalization of roughly $8.71 billion and reported trailing-twelve-month revenue of $67.67 million.
- Wall Street analysts maintain a strong buy consensus on the biotechnology firm with a mean price target of $109.20 ahead of its next earnings report.
Since the trade, $CYTK is up 0.4% after 1 week, down 5.6% after 1 month and down 26.5% to date (from the $85.19 close on Jun 30, 2026).
Get Cytokinetics, Incorporated text alerts
We text you when insiders, Congress, analysts or big funds move on $CYTK.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Cytokinetics, Incorporated alert may contain errors. Disclosures
Democratic Representative Gilbert Ray Cisneros Jr. picked up shares of Cytokinetics, Incorporated (NASDAQ: CYTK) in a trade executed on June 30, 2026. The transaction was revealed in a periodic transaction report filed under the STOCK Act on July 2, 2026. According to the congressional filing, the trade fell into a value range between $1,001 and $15,000. STOCK Act disclosures provide ranges rather than exact share quantities or dollar figures.
CYTK
Cytokinetics, Incorporated
Inside Rep. Gilbert Ray Cisneros Jr.'s Cytokinetics Trade
The Democrat from California's 31st district added the healthcare stock to his portfolio during the summer. This filing follows several other portfolio updates from the lawmaker, including reported stock purchases in WuXi AppTec, Enerpac Tool Group, and YETI Holdings over the preceding weeks. Periodic transaction reports filed under the Stop Trading on Congressional Knowledge Act give the public a look into the personal equity trades made by members of Congress.
Other Institutional Activity in Cytokinetics
Avoro Capital Advisors LLC grew its holdings by 1,666,666 shares, ending with 4,999,999 shares worth about $313.25 million in its report for the period ending June 30, 2026.
Cytokinetics, Incorporated Stock Up 1.1%
The biopharmaceutical company closed at $85.19 on the day of the representative's trade. The stock recently traded around $62.66 as of October 16, 2026.
Recent Earnings
Cytokinetics reported trailing-twelve-month revenue of $67.67 million alongside basic earnings per share of negative $7.22. The company is not currently profitable on a trailing basis. Watch for the next financial results release scheduled for November 4, 2026.
Insider Buying and Selling at Cytokinetics, Incorporated
Company insiders completed several sales over the late summer and early autumn. Director Robert E. Landry sold 1,000 shares at $72.13 on September 15, 2026. Officer Fady Ibraham Malik sold 3,500 shares at $68.29 on September 22, 2026, and another 3,500 shares at $61.38 on October 6, 2026. Chief Executive Officer Robert I. Blum sold 7,500 shares at $65.46 on September 28, 2026.
Analysts Set New Price Targets
Wall Street research firms updated their views on the stock following recent updates. RBC Capital maintains an outperform rating with a target of $112.00, down from $117.00, on August 7, 2026. Truist Securities maintains a buy rating, lifting its target to $112.00 from $106.00 on August 10, 2026. Barclays maintains an overweight rating and raised its target from $95.00 to $110.00 on August 13, 2026. JP Morgan maintains an overweight rating and raised its target from $97.00 to $103.00 on August 13, 2026. HC Wainwright & Co. reiterated a buy rating with a target of $140.00 on August 31, 2026. The stock carries a consensus strong buy rating and a mean price target of $109.20 across 20 analyst opinions.
About Cytokinetics, Incorporated
Cytokinetics is a South San Francisco, California-based biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors for serious illnesses. The firm markets MYQORZO, an oral cardiac myosin inhibitor used to treat symptomatic obstructive hypertrophic cardiomyopathy.
Bottom Line
Congressional stock disclosures offer transparency into personal investments made by elected officials. Observers will track future disclosure filings and the company's upcoming earnings report on November 4, 2026, for further updates.
Related Filing Alerts
Source: Gilbert Ray Cisneros Jr.'s STOCK Act disclosure on $CYTK (Jun 30, 2026). Written by software, not financial advice. How we make alerts